Epigenomics AG (STU:ECX) Institutional Ownership : 0.85% (As of May. 26, 2024)

View and export this data going back to . Start your Free Trial

What is Epigenomics AG Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Epigenomics AG's institutional ownership is 0.85%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Epigenomics AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Epigenomics AG's Float Percentage Of Total Shares Outstanding is 0.00%.

Epigenomics AG Institutional Ownership Historical Data

The historical data trend for Epigenomics AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Institutional Ownership Chart

Epigenomics AG Historical Data

The historical data trend for Epigenomics AG can be seen below:

	2021-02-28	2021-03-31	2021-04-30	2021-05-31	2021-06-30	2021-07-31	2021-08-31	2021-09-30	2021-10-31	2021-11-30
Institutional Ownership	2.27	1.25	1.25	0.69	0.56	0.56	0.56	0.85	0.85	0.85

Epigenomics AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Epigenomics AG (STU:ECX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (STU:ECX) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

EPGNF:USA

Address

Geneststrasse 5, Berlin, BB, DEU, 10829

Website

https://www.epigenomics.com

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.